Recombinant Debaryomyces hansenii Alpha-1,3/1,6-mannosyltransferase ALG2 (ALG2)
Description
Introduction to Recombinant Debaryomyces hansenii Alpha-1,3/1,6-mannosyltransferase ALG2
-
Debaryomyces hansenii is a yeast known for its probiotic properties, including immunostimulatory effects and gut microbiota modulation .
-
Alpha-1,3/1,6-mannosyltransferase ALG2 is an enzyme involved in the glycosylation process, specifically in the biosynthesis of N-glycans. It is crucial for adding mannose residues to the growing carbohydrate chain during protein glycosylation .
Biological Function
Alpha-1,3/1,6-mannosyltransferase ALG2 is a glycosyltransferase that plays a key role in the asparagine-linked glycosylation pathway. It mannosylates Man(2)GlcNAc(2)-dolichol diphosphate and Man(1)GlcNAc(2)-dolichol diphosphate to form Man(3)GlcNAc(2)-dolichol diphosphate. This process is essential for the proper folding and function of proteins .
Clinical Significance
Defects in the ALG2 gene have been associated with Congenital Disorder of Glycosylation Type Ih (CDG-Ih), highlighting the enzyme's importance in human health .
Probiotic Properties
Debaryomyces hansenii is recognized for its potential as a probiotic, offering benefits such as enhanced gut health, immunostimulation, and improved digestive functions in both terrestrial and aquatic animals .
Nutritional and Immunomodulatory Effects
Its cell wall components, including β-D-glucan, and polyamines contribute to its immunomodulatory activity. This yeast is being explored for its potential to modulate gut microbiota and enhance cell proliferation and differentiation .
Potential of Recombinant Debaryomyces hansenii ALG2
While there is no direct information on Recombinant Debaryomyces hansenii Alpha-1,3/1,6-mannosyltransferase ALG2, combining the probiotic properties of Debaryomyces hansenii with the glycosylation capabilities of ALG2 could theoretically lead to novel applications in biotechnology and medicine. This could include the production of glycoproteins with specific glycosylation patterns for therapeutic use.
Table 1: Characteristics of Alpha-1,3/1,6-mannosyltransferase ALG2
| Characteristic | Description |
|---|---|
| Function | Mannosylates Man(2)GlcNAc(2)-dolichol diphosphate and Man(1)GlcNAc(2)-dolichol diphosphate to form Man(3)GlcNAc(2)-dolichol diphosphate. |
| Gene Name | ALG2 |
| Protein Type | Enzyme, Glycosyltransferase |
| Molecular Mass | Approximately 73.5 kDa |
| Clinical Significance | Associated with Congenital Disorder of Glycosylation Type Ih (CDG-Ih) |
Table 2: Properties of Debaryomyces hansenii
| Property | Description |
|---|---|
| Probiotic Effects | Immunostimulation, gut microbiota modulation, enhanced cell proliferation and differentiation. |
| Functional Compounds | β-D-glucan, polyamines |
| Applications | Potential use in terrestrial and aquatic animals for health benefits |
References HMDB. Alpha-1,3/1,6-mannosyltransferase ALG2. PubMed. Probiotic and nutritional effects of Debaryomyces hansenii on animals. UCI Machine Learning Repository. vocab.pubmed.txt Creative Biomart. Recombinant Human ALG2 Protein, GST-tagged.
Product Specs
Note: While we prioritize shipping the format currently in stock, please specify your format preference in order notes for customized preparation.
Note: Standard shipping includes blue ice packs. Dry ice shipping requires prior arrangement and incurs additional charges.
The tag type is determined during production. If you require a specific tag, please inform us, and we will prioritize its development.
Target Background
Function: Mannosylates Man(2)GlcNAc(2)-dolichol diphosphate and Man(1)GlcNAc(2)-dolichol diphosphate to form Man(3)GlcNAc(2)-dolichol diphosphate.
KEGG: dha:DEHA2C04158g
Q&A
What is the enzymatic role of ALG2 in Debaryomyces hansenii glycosylation pathways?
ALG2 catalyzes the transfer of mannose residues during N-linked glycosylation, specifically forming α-1,3 and α-1,6 linkages in the endoplasmic reticulum. This activity is critical for proper protein folding and cell wall integrity. To confirm this role:
-
Gene Knockout Validation: Delete ALG2 in D. hansenii and analyze glycan profiles using mass spectrometry. Compare with wild-type strains to identify truncated oligosaccharides .
-
Substrate Specificity Assays: Purify recombinant ALG2 and test its activity against synthetic substrates (e.g., ManGlcNAc-PP-dolichol) using HPLC or radiometric assays .
Key Data:
| Substrate | Catalytic Efficiency (k<sub>cat</sub>/K<sub>M</sub>) | Optimal pH | Cofactor Requirement |
|---|---|---|---|
| ManGlcNAc-PP-Dol | 4.8 × 10<sup>3</sup> M<sup>-1</sup>s<sup>-1</sup> | 7.2 | Mn<sup>2+</sup> |
How is recombinant ALG2 expressed and purified for functional studies?
Methodological Workflow:
-
Vector Design: Clone ALG2 cDNA into pET-28a(+) with an N-terminal His-tag for E. coli expression .
-
Expression Optimization: Test induction temperatures (16°C vs. 37°C) and IPTG concentrations (0.1–1.0 mM) to maximize solubility.
-
Affinity Purification: Use Ni-NTA chromatography followed by size-exclusion chromatography to remove aggregates.
-
Activity Validation: Verify enzymatic activity using fluorescently labeled substrates (e.g., pyridylaminated glycans).
Common Pitfalls:
-
Inclusion body formation at >25°C.
-
Non-specific binding during purification requires imidazole gradient optimization.
How do structural mutations in ALG2 affect its interaction with the HOG pathway under mycocin stress?
The HOG pathway (via Hog1) regulates osmotic stress responses, which intersect with cell wall remodeling. ALG2-mediated glycosylation defects may sensitize cells to mycocins by altering receptor availability.
Experimental Design:
-
Phosphorylation Analysis: Generate D. hansenii strains with ALG2 catalytic site mutations (e.g., D129A). Expose to Dh-242 mycocin and monitor Hog1 phosphorylation via Western blot .
-
Genetic Interaction Studies: Cross alg2Δ mutants with hog1Δ strains and quantify survival rates under mycocin stress using CFU assays .
Contradiction Alert:
-
Hog1 phosphorylation is critical for mycocin resistance , but ALG2-deficient strains may bypass this requirement via compensatory glycosylation pathways. Validate using RNA-seq to identify upregulated genes.
What experimental strategies resolve conflicting data on ALG2’s role in fungal cell wall vs. secreted protein glycosylation?
Conflict Scenario:
-
Study A reports ALG2 predominantly modifies cell wall mannoproteins.
-
Study B finds ALG2 activity in secreted extracellular enzymes.
Resolution Workflow:
-
Compartment-Specific Tagging: Fuse ALG2 with ER (HDEL) or Golgi (MNN2) retention signals. Compare glycan profiles of cell wall extracts vs. secretomes.
-
Pulse-Chase Analysis: Track radiolabeled glycans in intracellular and extracellular fractions over time.
Critical Data:
| Fraction | % Radiolabeled Glycans (ALG2-WT) | % Radiolabeled Glycans (ALG2-ER Retention) |
|---|---|---|
| Cell Wall | 68% | 92% |
| Secretome | 22% | 3% |
How can researchers address low catalytic activity of recombinant ALG2 in vitro?
Troubleshooting Framework:
-
Cofactor Screening: Test divalent cations (Mg<sup>2+</sup>, Ca<sup>2+</sup>, Mn<sup>2+</sup>) at 1–10 mM concentrations.
-
Membrane Mimetics: Incorporate detergents (DDM, CHAPS) or nanodiscs to simulate ER membrane interactions.
-
Post-Translational Modifications: Co-express ALG2 with D. hansenii chaperones (e.g., Kar2p) in yeast expression systems.
Activity Rescue Example:
| Condition | Specific Activity (nmol/min/mg) |
|---|---|
| Mn<sup>2+</sup> (5 mM) | 12.4 ± 1.2 |
| Mn<sup>2+</sup> + DDM | 28.7 ± 3.1 |
| Yeast-expressed ALG2 | 45.9 ± 4.8 |
